Newsfeeds - Spark Newswire

1 minute read

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

April 1, 3:27 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.

VRTX

1 minute read

Markets Tumble To Conclude Action-Packed Q1

By Henry Khederian

March 31, 4:13 PM

U.S. indices finished lower to conclude the first quarter as investors continue to weigh Russia-Ukraine developments and Fed rate hike outlook.

AMD

1 minute read

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

By Vandana Singh

March 31, 1:20 PM

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked…

VRTX

4 minute read

Vertex Pharma Reports Statistically Significant, Clinically Meaningful Results From 2 Phase 2 Proof-Of-Concept Studies Of VX-548 For Treatment Of Acute Pain; Treatment Met Primary Endpoint

By Benzinga Newsdesk

March 31, 8:02 AM

- Treatment with the NaV1.8 inhibitor VX-548 met the primary endpoint in both Phase 2 proof-of-concept acute pain studies following abdominoplasty or bunionectomy surgery - - VX-548 was generally well tolerated -

VRTX

1 minute read

FDA
News

Health Canada Grants Marketing Authorization For Kalydeco For Patients With Cystic Fibrosis Between The Ages Of 4 Months And 18 Years With The R117H Mutation In The CFTR Gene

By Benzinga Newsdesk

March 25, 8:05 AM

Vertex Pharmaceuticals (Canada) Incorporated (NASDAQ:VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrKALYDECO® (ivacaftor) in patients from 4

VRTX

2 minute read

Cathie Wood’s Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings

By Shanthi Rexaline

February 5, 11:09 AM

Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.

ARKG

5 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For February 3, 2022

By Benzinga Insights

February 3, 11:04 AM

AEM

1 minute read

RBC Capital Downgrades Vertex Pharmaceuticals to Sector Perform, Announces $269 Price Target

By Benzinga Newsdesk

February 3, 6:21 AM

RBC Capital analyst Brian Abrahams downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Outperform to Sector Perform and announces $269 price target.

VRTX

1 minute read

Earnings

Recap: Vertex Pharmaceuticals Q4 Earnings

By Benzinga Insights

January 26, 5:18 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

VRTX

1 minute read

Vertex Sees FY22 Product Revenue $8.4B-$8.6B

By Benzinga Newsdesk

January 26, 5:05 PM

Full Year 2022 Financial Guidance Vertex today provided full year 2022 financial guidance. Vertex's product revenue guidance is primarily based on expectations for continued strong performance of

VRTX